bermekimab: Clinical Trials

9 trials of bermekimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated. 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 29Completed 6, Terminated 3

Follow bermekimab: new trials by email Literature Review of bermekimab trials Research Report on bermekimab

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
Bermekimab, Adalimumab, Placebo - Hidradenitis Suppurativa
Phase 2TerminatedJanssen Research & Development, LLC1512021-10-122023-11-13
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Bermekimab, Placebo - Dermatitis, Atopic
Phase 2TerminatedJanssen Research & Development, LLC62021-09-022023-05-24
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Placebo, Bermekimab, Dupilumab - Dermatitis, Atopic
Phase 2TerminatedJanssen Research & Development, LLC1992021-05-032023-03-01
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
bermekimab, placebo - Hidradenitis Suppurativa, Acne Inversa
Phase 2CompletedJanssen Research & Development, LLC1532019-09-162023-07-27
The Benefit of Bermekimab in Patients With Systemic Sclerosis
MABp1 (Bermekimab) OR Placebo, MABp1 (Bermekimab) - Scleroderma, Systemic
Phase 2CompletedHellenic Institute for the Study of Sepsis202019-07-192022-09-29
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
Xilonix - Pyoderma Gangrenosum
Phase 2CompletedJanssen Research & Development, LLC102014-01-312025-07-08
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
RA-18C3 - Acne Vulgaris
Phase 2CompletedJanssen Research & Development, LLC112012-02-292025-03-30
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
RA-18C3 - Psoriasis
Phase 2CompletedJanssen Research & Development, LLC82011-09-302025-03-30
Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.
CV-18C3, Standard of Care - Patients Undergoing Repeat Peripheral Artery Revascularization
Phase 2CompletedJanssen Research & Development, LLC432011-06-302025-03-30

Conditions studied

Dermatitis, Atopic (2)  ·  Hidradenitis Suppurativa (2)  ·  Acne Vulgaris (1)  ·  Psoriasis (1)  ·  Pyoderma Gangrenosum (1)  ·  Scleroderma, Systemic (1)

Sponsors

Janssen Research & Development, LLC (8)  ·  Hellenic Institute for the Study of Sepsis (1)

Countries

United States (8)  ·  Canada (2)  ·  Germany (2)  ·  Japan (2)  ·  Poland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Greece (1)  ·  Netherlands (1)  ·  Spain (1)

Top investigators

Hosam El-Sayed, M.D., Ph.D. (1)  ·  Johann Gudjonsson, M.D., PhD (1)  ·  Michael D Stecher, MD (1)

Results publications

PMID 26433546